Thomas Jahn

Thomas Jahn is an experienced clinical development leader with a strong background in hematology and oncology. Current position as Global Clinical Program Lead at AstraZeneca follows prior roles including Vice President Clinical Development at RAPT Therapeutics and Apexigen, as well as Chief Medical Officer at Trishula Therapeutics, Inc. Previous experience includes serving as Senior Medical Director at AbbVie, where clinical development of bcl-2 family inhibitors was a focus, and Director of Clinical Research at Gilead Sciences, specializing in PI3K inhibitors. Education history includes a Doctorate in Hematology/Immunology from Medizinische Hochschule Hannover, an M.D. from the University of Göttingen, and additional qualifications from Stanford University School of Medicine and the University of California, Santa Cruz. Thomas Jahn has also held academic roles, including Assistant Professor at the University of Southern California and Instructor of Pediatrics at Stanford University.